PMID- 19143943
OWN - NLM
STAT- MEDLINE
DCOM- 20091214
LR  - 20220316
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 14
IP  - 6
DP  - 2009 Sep
TI  - Urinary levels of epidermal growth factor, interleukin-6 and monocyte 
      chemoattractant protein-1 may act as predictor markers of renal function outcome 
      in immunoglobulin A nephropathy.
PG  - 613-20
LID - 10.1111/j.1440-1797.2008.01051.x [doi]
AB  - AIM: Urinary cytokine excretion may reflect histological changes in 
      immunoglobulin A nephropathy (IgAN), and their measurement can give information 
      about disease outcome. METHODS: Thirty-three IgAN patients were prospectively 
      followed for 5.6 +/- 3.1 years. Urinary levels of monocyte chemoattractant 
      protein-1 (MCP-1), interleukin (IL)-6 and epidermal growth factor (EGF) were 
      measured at diagnosis and repeated 1 year later for IL-6 and EGF. RESULTS: 
      Urinary MCP-1 and IL-6 levels were increased significantly, while EGF excretion 
      reduced in IgAN patients, compared to controls. IL-6 urinary levels showed 
      significant positive correlation with chronic histological lesions. Patients were 
      classified into five groups, according to the Haas classification system. MCP-1 
      and IL-6 urinary levels were increased, whereas EGF levels were reduced in the 
      progression of staging. EGF urinary excretion was a strong predictor factor of 
      disease outcome, significantly correlated with creatinine clearance at time of 
      diagnosis (r = 0.5, P = 0.005), and at the end of follow up (r = 0.6, P = 0.001). 
      Urinary EGF levels measured a year later could predict long-term outcome better, 
      and a cut of 0.05 pg/mg urine creatinine levels could distinguish between 
      progressors and non-progressors. CONCLUSION: Urinary MCP-1, IL-6 and EGF levels 
      may represent histology in IgAN. EGF excretion can be a predictive marker and its 
      serial measurements may give information about disease outcome and the effect of 
      treatment.
FAU - Stangou, Maria
AU  - Stangou M
AD  - Department of Nephrology, Aristotle University of Thessaloniki, Thessaloniki, 
      Greece. mstangou@math.com
FAU - Alexopoulos, Efstathios
AU  - Alexopoulos E
FAU - Papagianni, Aikaterini
AU  - Papagianni A
FAU - Pantzaki, Afroditi
AU  - Pantzaki A
FAU - Bantis, Christos
AU  - Bantis C
FAU - Dovas, Spiros
AU  - Dovas S
FAU - Economidou, Domniki
AU  - Economidou D
FAU - Leontsini, Maria
AU  - Leontsini M
FAU - Memmos, Dimitrios
AU  - Memmos D
LA  - eng
PT  - Journal Article
DEP - 20090108
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Chemokine CCL2/*urine
MH  - Epidermal Growth Factor/*urine
MH  - Female
MH  - Glomerulonephritis, IGA/pathology/physiopathology/*urine
MH  - Humans
MH  - Interleukin-6/*urine
MH  - Kidney/*physiopathology
MH  - Male
MH  - Middle Aged
EDAT- 2009/01/16 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/01/16 09:00
PHST- 2009/01/16 09:00 [entrez]
PHST- 2009/01/16 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - NEP1051 [pii]
AID - 10.1111/j.1440-1797.2008.01051.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2009 Sep;14(6):613-20. doi: 
      10.1111/j.1440-1797.2008.01051.x. Epub 2009 Jan 8.